Study of HS-10517 in Chinese Adult Participants

NCT05779579 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

340

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

DRUG: HS-10517 Dose 1
DRUG: HS-10517 Dose 2
DRUG: HS-10517 Dose 3
DRUG: HS-10517 Dose 4
DRUG: Placebo

Sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.